Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.
Fierro CA, Sarnecki M, Doua J, Spiessens B, Go O, Davies TA, van den Dobbelsteen G, Poolman J, Abbanat D, Haazen W. Fierro CA, et al. Among authors: spiessens b. Open Forum Infect Dis. 2023 Aug 11;10(8):ofad417. doi: 10.1093/ofid/ofad417. eCollection 2023 Aug. Open Forum Infect Dis. 2023. PMID: 37608916 Free PMC article.
Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study.
Doua J, Ekkelenkamp M, Verheij T, Go O, Ruhmel S, Leathers K, Spiessens B, van Rooij S, Fowler VG Jr, Geurtsen J, Dolor R, Sarnecki M, Chatterjee R, Poolman J, Bonten M; on behalf COMBACTE-NET consortium/EXPECT study group. Doua J, et al. Among authors: spiessens b. Eur J Clin Microbiol Infect Dis. 2024 Mar;43(3):541-550. doi: 10.1007/s10096-023-04738-y. Epub 2024 Jan 18. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38236365 Free PMC article.
Clinical presentation and antimicrobial resistance of invasive Escherichia coli disease in hospitalized older adults: a prospective multinational observational study.
Doua J, Rodríguez-Baño J, Froget R, Puranam P, Go O, Geurtsen J, van Rooij S, Vilken T, Minoru I, Yasumori I, Spiessens B, Tacconelli E, Biehl LM, Thaden JT, Sarnecki M, Goossens H, Poolman J, Bonten M, Ekkelenkamp M; COMBACTE-NET Consortium/EXPECT Study Group. Doua J, et al. Among authors: spiessens b. Infection. 2024 Jan 25. doi: 10.1007/s15010-023-02163-z. Online ahead of print. Infection. 2024. PMID: 38267801
Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.
Watson-Jones D, Kavunga-Membo H, Grais RF, Ahuka S, Roberts N, Edmunds WJ, Choi EM, Roberts CH, Edwards T, Camacho A, Lees S, Leyssen M, Spiessens B, Luhn K, Douoguih M, Hatchett R, Bausch DG, Muyembe JJ; DRC-EB-001 protocol writing team. Watson-Jones D, et al. Among authors: spiessens b. BMJ Open. 2022 Mar 8;12(3):e055596. doi: 10.1136/bmjopen-2021-055596. BMJ Open. 2022. PMID: 35260458 Free PMC article.
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
Bockstal V, Leyssen M, Heerwegh D, Spiessens B, Robinson C, Stoop JN, Roozendaal R, Van Effelterre T, Gaddah A, Van Roey GA, Solforosi L, Zahn R, Callendret B, Hendriks J, Luhn K, Douoguih M, Schuitemaker H, Van Hoof J. Bockstal V, et al. Among authors: spiessens b. NPJ Vaccines. 2022 Nov 30;7(1):156. doi: 10.1038/s41541-022-00564-z. NPJ Vaccines. 2022. PMID: 36450746 Free PMC article.
Distribution of extraintestinal pathogenic Escherichia coli O-serotypes and antibiotic resistance in blood isolates collected from patients in a surveillance study in Japan.
Matsumoto T, Mikamo H, Ohge H, Yanagihara K, Weerdenburg E, Go O, Spiessens B, van Geet G, van den Hoven T, Momose A, Hagiwara Y, Nakayama Y, Poolman J, Geurtsen J, Kaku M. Matsumoto T, et al. Among authors: spiessens b. J Infect Chemother. 2022 Nov;28(11):1445-1451. doi: 10.1016/j.jiac.2022.07.001. Epub 2022 Jul 16. J Infect Chemother. 2022. PMID: 35843539
Global Distribution of O Serotypes and Antibiotic Resistance in Extraintestinal Pathogenic Escherichia coli Collected From the Blood of Patients With Bacteremia Across Multiple Surveillance Studies.
Weerdenburg E, Davies T, Morrow B, Zomer AL, Hermans P, Go O, Spiessens B, van den Hoven T, van Geet G, Aitabi M, DebRoy C, Dudley EG, Bonten M, Poolman J, Geurtsen J. Weerdenburg E, et al. Among authors: spiessens b. Clin Infect Dis. 2023 Feb 8;76(3):e1236-e1243. doi: 10.1093/cid/ciac421. Clin Infect Dis. 2023. PMID: 35684979 Free PMC article.
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Van Dromme I, Spiessens B, Vingerhoets J, Custers J, Scheper G, Robb ML, Treanor J, Ryser MF, Barouch DH, Swann E, Marovich MA, Neuzil KM, Corey L, Stoddard J, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Sadoff J, et al. Among authors: spiessens b. N Engl J Med. 2022 Mar 3;386(9):847-860. doi: 10.1056/NEJMoa2117608. Epub 2022 Feb 9. N Engl J Med. 2022. PMID: 35139271 Free PMC article. Clinical Trial.
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Sadoff J, et al. Among authors: spiessens b. N Engl J Med. 2021 Jun 10;384(23):2187-2201. doi: 10.1056/NEJMoa2101544. Epub 2021 Apr 21. N Engl J Med. 2021. PMID: 33882225 Free PMC article. Clinical Trial.
40 results